Study Summary
The purposed of this study is to determine whether an infusion with specialized 'modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker will reduce the risk of relapse after transplant.
Want to learn more about this trial?
Request More InfoInterventions
CAR T-Cell InfusionBIOLOGICAL
Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |